BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  China

  AstraZeneca Names New International Operations Lead Amid Probe on China Exec

  Iskra Reic will continue to serve as the pharma’s senior vice president for Vaccines and Immune Therapies as she steps in for Leon Wang, who was detained by Chinese authorities in November.

  December 5, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Novo Continues Manufacturing Spending Spree With $400M Denmark Expansion, $200M Plant Purchase

  In recent months Novo Nordisk has invested several billions of dollars to boost its manufacturing capacity—including its highly contested $16.5 billion merger with CDMO giant Catalent.

  December 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  How Trump’s Immigration Policies Could Affect Biopharma Professionals’ Work Visas

  Based on how President-elect Donald Trump’s first administration handled immigration, experts are concerned about how his second term will impact foreign-born biopharma professionals. Two immigration attorneys discuss what may be ahead, including increased difficulty getting work visas.

  December 5, 2024

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Drug pricing

  Bluebird, Vertex/CRISPR’s SCD Gene Therapies Get New CMS Payment Model

  The payment scheme will tie gene therapy payments to improvements in health outcomes—and could potentially boost the uptake of these sickle cell disease treatments.

  December 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Previous Investment Patterns Set to Repeat in 2025

  In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss how a slow and steady pace is a continuation of the pattern we have seen throughout the last three years.

  December 5, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Legal

  Novartis Loses Appeal to Bar Entresto Generic From U.S. Market

  Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.

  December 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Funding

  Nuvig Ropes in $161M Series B From Big Pharma Players for Autoimmune Indications

  California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, BMS and others for its Fc fragment immunomodulator aimed at improving autoimmune dysregulation.

  December 5, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Alzheimer’s disease

  GSK Strikes Third Agreement This Week, Leans Further Into Neuro

  The Muna partnership will give GSK access to Muna’s MiND-MAP platform, which it will apply to postmortem brain samples to identify potential therapeutic targets for Alzheimer’s disease.

  December 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  The Multiple Myeloma Research Foundation (MMRF) Announces the First Patient Enrolled in its Horizon Clinical Trials Program to Accelerate the Identification of Optimal Treatment Strategies for Multiple Myeloma

  December 5, 2024

   · 

  3 min read
• Press Releases

  Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

  December 5, 2024

   · 

  18 min read